Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.52244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Tingwei Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Disease Progression. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Hunan Innovative Province Construction Project, National Key Research and Development Program of China.
Abstract (Originalsprache)
Objective
We established a prospective cohort study to investigate the differences in motor and non‐motor symptoms between idiopathic Parkinson's disease (IPD) and Parkinson's disease in carriers of leucine‐rich repeat kinase 2 (LRRK2) gene risk variants (LRRK2‐PD).
Methods
The study included 1407 individuals with IPD and 649 individuals with LRRK2‐PD (comprising 304 with LRRK2‐G2385R, 220 with LRRK2‐R1628P, and 105 with LRRK2‐A419V). Differences in symptoms between LRRK2‐PD and IPD were analyzed using LCMM modeling and Cox regression analysis.
Results
The LRRK2‐G2385R variant showed slower progression in tremor symptoms and excessive daytime sleepiness compared with IPD. In contrast, symptoms associated with LRRK2‐R1628P and LRRK2‐A419V were more similar to those of IPD. Survival analysis revealed that LRRK2‐PD does not affect life expectancy compared with IPD.
Interpretation
Our extended longitudinal follow‐up of LRRK2‐PD in the Chinese population provided valuable insights, further confirming the clinical characteristics of the three LRRK2 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Nuclear Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Neurology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Changsha, Hunan, China.
- National Clinical Research Centre for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
ORCID-Profile: Tingwei Song, Beisha Tang, Lifang Lei, Qian Xu
Förderung
- National Natural Science Foundation of China
- Hunan Innovative Province Construction Project
- National Key Research and Development Program of China
Zitieren
APA
Song, T., Zhou, X., Wang, C., Wu, H., Yan, X., Guo, J., Tang, B., Lei, L., Xu, Q., & Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD‐MDCNC) (2025). Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52244
Vancouver
Song T, Zhou X, Wang C, Wu H, Yan X, Guo J, et al. Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.52244
BibTeX
@article{Song2025,
author = {Song, Tingwei and Zhou, Xiaoxia and Wang, Chunyu and Wu, Heng and Yan, Xinxiang and Guo, Jifeng and Tang, Beisha and Lei, Lifang and Xu, Qian and Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD‐MDCNC), Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD‐MDCNC)},
title = {Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.52244}
}
EUVIMED